Roche’s Tecentriq gains first-line approval in NSCLC but Merck’s Keytruda dominates the space

28th May 2020 (Last Updated May 28th, 2020 13:52)

Earlier this month, Roche's Tecentriq (atezolizumab) gained FDA approval as first-line monotherapy to treat metastatic non-small cell lung cancer (NSCLC), becoming the fourth approval in the indication, as well as the fifth approval in lung cancer as a whole.

The approval comes from data of the Phase III Impower110 trial, which concluded an overall survival benefit in patients with high PD-L1 expression. Read more here.